| MeSH term | MeSH ID | Detail |
|---|---|---|
| Ureteral Obstruction | D014517 | 10 associated lipids |
| Rodent Diseases | D012376 | 4 associated lipids |
| Osteomyelitis | D010019 | 10 associated lipids |
| Pancreatitis | D010195 | 10 associated lipids |
| Skin Ulcer | D012883 | 6 associated lipids |
| Cysts | D003560 | 4 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
| Wheeldon TU et al. | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848630 |
| Dalla Libera M et al. | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730251 |
| Labenz J et al. | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730252 |
| Chacko Y and Holtmann GJ | Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? | 2011 | Aliment. Pharmacol. Ther. | pmid:21679208 |
| Nseir W et al. | Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. | 2012 | Aliment. Pharmacol. Ther. | pmid:22646167 |
| Zullo A et al. | High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. | 2005 | Aliment. Pharmacol. Ther. | pmid:15948808 |
| Gisbert JP and Calvet X | Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. | 2012 | Aliment. Pharmacol. Ther. | pmid:22129228 |
| Bühling A et al. | Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552917 |
| Hokari K et al. | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552922 |
| Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
| Kamberoglou D et al. | Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552924 |
| Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
| Harb AH et al. | Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. | 2015 | Aliment. Pharmacol. Ther. | pmid:26011564 |
| al-Assi MT et al. | Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986970 |
| Neri M et al. | Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986974 |
| Lai KC et al. | Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641502 |
| Zullo A et al. | High eradication rates of Helicobacter pylori with a new sequential treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641522 |
| Spinzi GC et al. | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735926 |
| Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
| Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
| Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
| Harris AW et al. | Eradication of Helicobacter pylori with lansoprazole and clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605863 |
| Katelaris PH et al. | A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605864 |
| Yousfi MM et al. | Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605865 |
| Sheu BS et al. | Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856088 |
| Choi IJ et al. | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856089 |
| Bazzoli F et al. | Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856090 |
| Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
| Cestari R | Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798804 |
| Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
| Spadaccini A et al. | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798805 |
| Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
| Bortolotti M et al. | Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798808 |
| Iijima K et al. | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15153171 |
| Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121908 |
| Spadaccini A et al. | Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8899094 |
| Gisbert JP et al. | Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012477 |
| Mason JM et al. | Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. | 2008 | Aliment. Pharmacol. Ther. | pmid:18793340 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Williams MP et al. | Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305479 |
| Janssen MJ et al. | A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328254 |
| Tankovic J et al. | Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328266 |
| Chi CH et al. | Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. | 2003 | Aliment. Pharmacol. Ther. | pmid:12895220 |
| Higuchi K et al. | Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492739 |
| Coelho LG et al. | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492742 |
| Feydt-Schmidt A et al. | Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. | 2002 | Aliment. Pharmacol. Ther. | pmid:12452940 |
| Colin R | Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030959 |